Home> Products> Inhibitors> Lurasidone-CAS 367514-87-2
price inquiry for CAS:367514-87-2, Product:Lurasidone
For research use only. We do not sell to patients.

Lurasidone CAS: 367514-87-2

Category: Inhibitors
Product Name: Lurasidone
Cat No: I000004
CAS No: 367514-87-2
Synonyms: Lurasidone base
Molecular Formula: C28H36N4O2S
Molecular Weight: 492.7
SMILES: [H][C@@]1(C2=O)[C@]([C@H]3CC[C@@H]1C3)([H])C(N2C[C@@H]4CCCC[C@H]4CN5CCN(C6=NSC7=C6C=CC=C7)CC5)=O
InChIKey: PQXKDMSYBGKCJA-CVTJIBDQSA-N
Solubility: Soluble in DMSO
Target: adrenergic receptor
Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years)
CAS 367514-87-2,Lurasidone
  • Description

Lurasidone(cas 367514-87-2) is a new atypical antipsychotic. I is also approved for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults when used alone or in combination with lithium or valproate. Lurasidone acts as an antagonist of the following sites: α1-adrenergic receptor (Ki = 48 nM); α2A-adrenergic receptor (Ki = 1.6 nM); α2C-adrenergic receptor (Ki = 10.8 nM); D1 receptor (Ki = 262 nM); D2 receptor (Ki = 1.7 nM); 5-HT2A receptor (Ki = 2.0 nM); 5-HT2C receptor (Ki = 415 nM); 5-HT7 receptor (Ki = 0.5 nM). And as a partial agonist of the following sites: 5-HT1A receptor (Ki = 6.8 nM). (Source: http://en.wikipedia.org/wiki/Lurasidone).


  • Spec

Appearance: Powder
Purity: 98.0%

  • References

1:Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial. Sramek J, Loebel A, Murphy M, Mao Y, Pikalov A, Cutler NR.Prog Neuropsychopharmacol Biol Psychiatry. 2017 May 9. pii: S0278-5846(16)30348-7. doi: 10.1016/j.pnpbp.2017.05.002. [Epub ahead of print] PMID: 28499900
2:[Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia]. Zheng Q, Liu B, Xu S, Liao M, Zhang Y, Li L.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Apr 28;42(4):476-480. doi: 10.11817/j.issn.1672-7347.2017.04.018. Chinese. PMID: 28490709 Free Article
3:Lurasidone associated neutropenia. Singh S, Ahmad H, John AP.Aust N Z J Psychiatry. 2017 May 1:4867417708869. doi: 10.1177/0004867417708869. [Epub ahead of print] No abstract available. PMID: 28478684
4:Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Goldman R, Loebel A, Cucchiaro J, Deng L, Findling RL.J Child Adolesc Psychopharmacol. 2017 May 5. doi: 10.1089/cap.2016.0189. [Epub ahead of print] PMID: 28475373
5:Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension-CORRIGENDUM. Goldberg JF, Ng-Mak D, Siu C, Chuang CC, Rajagopalan K, Loebel A.CNS Spectr. 2017 May 2:1. doi: 10.1017/S1092852917000281. [Epub ahead of print] No abstract available. PMID: 28463099
6:Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Li J, Yoshikawa A, Brennan MD, Ramsey TL, Meltzer HY.Schizophr Res. 2017 Apr 18. pii: S0920-9964(17)30196-2. doi: 10.1016/j.schres.2017.04.009. [Epub ahead of print] PMID: 28431800
7:Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. Tsai J, Thase ME, Mao Y, Ng-Mak D, Pikalov A, Loebel A.CNS Spectr. 2017 Apr;22(2):236-245. doi: 10.1017/S1092852917000074. Epub 2017 Mar 30. PMID: 28357969
8:Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A.CNS Spectr. 2017 Apr;22(2):228-235. doi: 10.1017/S1092852917000232. Epub 2017 Mar 16. PMID: 28300012
9:Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension. Goldberg JF, Ng-Mak D, Siu C, Chuang CC, Rajagopalan K, Loebel A.CNS Spectr. 2017 Apr;22(2):220-227. doi: 10.1017/S1092852917000025. Epub 2017 Mar 7. PMID: 28264739
10:Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A.World J Biol Psychiatry. 2017 Mar 7:1-11. doi: 10.1080/15622975.2017.1285050. [Epub ahead of print] PMID: 28264635


price inquiry for CAS:367514-87-2, Product:Lurasidone